The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
LauferM., RamalingamS., SchoenbergM.P.Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol.2003; 21(4): 697–703.
2.
WitjesJ.A., van der HeijdenA.G., VriesemaJ.L.Intravesical gemcitabine: a phase I and pharmacokinetic study. Eur Urol.2004; 45(2): 182–186.
3.
PalouJ., CarcasA., SegarraJ.Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. J Urol.2004; 172(2): 485–488.
4.
De BerardinisE., AntoniniG., PetersG.J.Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU Int.2004; 93(4): 491–494.
5.
DalbagniG., RussoP., SheinfeldJ.Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol.2002; 20(15): 3193–3198.
6.
BartolettiR., GacciM., PaoliniR.Intravesical gemcitabine in medium/high risk superficial transitional cell carcinoma of the bladder: a phase II study [abstract 1719]. Proc Am Soc Clin Oncol.2003; 22: 428.
7.
BouzidK., FerhatR., BounedjarA.Intravesical gemcitabine (G) single agent as adjuvant chemotherapy in superficial transitional cell carcinoma (TCC) of bladder [abstract 4601]. J Clin Oncol.2004; 22(14S): 407s.
8.
BuettnerH., StoffregenC., HeyerJ.Immediate postoperative instillation of gemcitabine after transurethral resection of bladder tumors [abstract 4685]. J Clin Oncol.2004; 22(14S): 427s.
